nach oben

Heart Failure Reviews

Erschienen in:

01.07.2015

Effects of apelin on the cardiovascular system

verfasst von: Anna Folino, Pier Giorgio Montarolo, Michele Samaja, Raffaella Rastaldo

Erschienen in: Heart Failure Reviews | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Apelin is an endogenous peptide acting on the APJ receptor. It consists of several isoforms characterized by different numbers of amino acids. The number of amino acids in the active isoforms range from 36 to 12. Apelin-13 and, to a lesser extent, apelin-36 are considered the most active isoforms with the greatest activity on the cardiovascular homeostasis. The effects normally exerted by the basal level of endogenous apelin can be enhanced not only by its up-regulation, but may also by its exogenous administration. The present review considers the effects of apelin on various aspects of the cardiovascular function, such as cardiac development, vasomotor tone, angiogenesis, myocardial inotropy in healthy and failing hearts as well as the prevention of ischemia–reperfusion injury, cardiac fibrosis and remodeling. Also the biphasic changes in apelin level during the evolution of heart failure are considered. Although the positive inotropic effect exerted by apelin in normal and failing hearts would suggest the use of this peptide in the treatment of heart failure, the limited duration and extent of its effect do not support this possibility, unless a long-lasting (6 h) infusion is performed to overcome the limit of its short life. However, although the data on the characteristics of the inotropic activity do not provide a strong support for the treatment of active heart failure, apelin may be used in the prevention of heart failure because of its activity in limiting the consequences of myocardial ischemia such as infarct size and cardiac remodeling.

O′Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136(1–2):355–360PubMed

Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251(2):471–476. doi:10.1006/bbrc.1998.9489 PubMed

Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y, Osmond DH, George SR, Oâ€™Dowd BF (2000) Characterization of apelin, the ligand for the APJ receptor. J Neurochem 74(1):34–41PubMed

Simpkin JC, Yellon DM, Davidson SM, Lim SY, Wynne AM, Smith CC (2007) Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia–reperfusion injury. Basic Res Cardiol 102(6):518–528. doi:10.1007/s00395-007-0671-2 PubMed

Zhou N, Zhang X, Fan X, Argyris E, Fang J, Acheampong E, DuBois GC, Pomerantz RJ (2003) The N-terminal domain of APJ, a CNS-based coreceptor for HIV-1, is essential for its receptor function and coreceptor activity. Virology 317(1):84–94PubMed

Zhen EY, Higgs RE, Gutierrez JA (2013) Pyroglutamyl apelin-13 identified as the major apelin isoform in human plasma. Anal Biochem 442(1):1–9. doi:10.1016/j.ab.2013.07.006 PubMed

Masri B, Knibiehler B, Audigier Y (2005) Apelin signalling: a promising pathway from cloning to pharmacology. Cell Signal 17(4):415–426. doi:10.1016/j.cellsig.2004.09.018 PubMed

Maguire JJ, Kleinz MJ, Pitkin SL, Davenport AP (2009) [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54(3):598–604. doi:10.1161/HYPERTENSIONAHA.109.134619 PubMed

Kleinz MJ, Davenport AP (2005) Emerging roles of apelin in biology and medicine. Pharmacol Ther 107(2):198–211. doi:10.1016/j.pharmthera.2005.04.001 PubMed

10.

Kleinz MJ, Davenport AP (2004) Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118(3):119–125. doi:10.1016/j.regpep.2003.11.002 PubMed

11.

Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T (2010) Effects of olmesartan on Apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 55(1):83–88. doi:10.1097/FJC.0b013e3181c87a82 PubMed

12.

Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, Mayranpaa M, Sarman B, Seres L, Skoumal R, Lako-Futo Z, deChatel R, Ruskoaho H, Toth M (2003) Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 308(3):480–485PubMed

13.

De Mota N, Reaux-Le Goazigo A, El Messari S, Chartrel N, Roesch D, Dujardin C, Kordon C, Vaudry H, Moos F, Llorens-Cortes C (2004) Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA 101(28):10464–10469. doi:10.1073/pnas.0403518101 PubMedCentralPubMed

14.

Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C (2008) Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol JASN 19(5):1015–1024. doi:10.1681/ASN.2007070816

15.

Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NR, Sharma S, Neilson I, Webb DJ, Megson IL, Flapan AD, Newby DE (2008) Vascular effects of apelin in vivo in man. J Am Coll Cardiol 52(11):908–913. doi:10.1016/j.jacc.2008.06.013 PubMed

16.

Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M (2000) Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 275(28):21061–21067. doi:10.1074/jbc.M908417199 PubMed

17.

Farkasfalvi K, Stagg MA, Coppen SR, Siedlecka U, Lee J, Soppa GK, Marczin N, Szokodi I, Yacoub MH, Terracciano CM (2007) Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 357(4):889–895. doi:10.1016/j.bbrc.2007.04.017 PubMed

18.

Charo DN, Ho M, Fajardo G, Kawana M, Kundu RK, Sheikh AY, Finsterbach TP, Leeper NJ, Ernst KV, Chen MM, Ho YD, Chun HJ, Bernstein D, Ashley EA, Quertermous T (2009) Endogenous regulation of cardiovascular function by apelin-APJ. Am J Physiol Heart Circ Physiol 297(5):H1904–H1913. doi:10.1152/ajpheart.00686.2009 PubMedCentralPubMed

19.

Chng SC, Ho L, Tian J, Reversade B (2013) ELABELA: a hormone essential for heart development signals via the apelin receptor. Dev Cell 27(6):672–680. doi:10.1016/j.devcel.2013.11.002 PubMed

20.

Xie F, Lv D, Chen L (2014) ELABELA: a novel hormone in cardiac development acting as a new endogenous ligand for the APJ receptor. Acta Biochim Biophys Sin 46(7):620–622. doi:10.1093/abbs/gmu032 PubMed

21.

Scimia MC, Hurtado C, Ray S, Metzler S, Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, Bueno OF, Vlasuk GP, Kaliman P, Bodmer R, Smith LH, Ashley E, Mercola M, Brown JH, Ruiz-Lozano P (2012) APJ acts as a dual receptor in cardiac hypertrophy. Nature 488(7411):394–398. doi:10.1038/nature11263 PubMedCentralPubMed

22.

Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M (2001) The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99(2–3):87–92PubMed

23.

Cheng X, Cheng XS, Pang CC (2003) Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 470(3):171–175PubMed

24.

Ashley EA, Powers J, Chen M, Kundu R, Finsterbach T, Caffarelli A, Deng A, Eichhorn J, Mahajan R, Agrawal R, Greve J, Robbins R, Patterson AJ, Bernstein D, Quertermous T (2005) The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65(1):73–82. doi:10.1016/j.cardiores.2004.08.018 PubMedCentralPubMed

25.

Berry MF, Pirolli TJ, Jayasankar V, Burdick J, Morine KJ, Gardner TJ, Woo YJ (2004) Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110(11 Suppl 1):II187–II193. doi:10.1161/01.CIR.0000138382.57325.5c PubMed

26.

Ferrario CM (2006) Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst JRAAS 7(1):3–14. doi:10.3317/jraas.2006.003

27.

Higuchi S, Ohtsu H, Suzuki H, Shirai H, Frank GD, Eguchi S (2007) Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci 112(8):417–428. doi:10.1042/CS20060342 PubMed

28.

Siddiquee K, Hampton J, McAnally D, May L, Smith L (2013) The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition. Br J Pharmacol 168(5):1104–1117. doi:10.1111/j.1476-5381.2012.02192.x PubMedCentralPubMed

29.

Kazemi-Bajestani SM, Patel VB, Wang W, Oudit GY (2012) Targeting the ACE2 and apelin pathways are novel therapies for heart failure: opportunities and challenges. Cardiol Res Pract 2012:823193. doi:10.1155/2012/823193 PubMedCentralPubMed

30.

Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, Kimura A, Ito H, Penninger JM, Imai Y, Kuba K (2013) Apelin is a positive regulator of ACE2 in failing hearts. J Clin Invest 123(12):5203–5211. doi:10.1172/JCI69608 PubMedCentralPubMed

31.

Catt KJ, Mendelsohn FA, Millan MA, Aguilera G (1984) The role of angiotensin II receptors in vascular regulation. J Cardiovasc Pharmacol 6(Suppl 4):S575–S586PubMed

32.

Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T (2008) Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118(10):3343–3354. doi:10.1172/JCI34871 PubMedCentralPubMed

33.

Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama K, Nishimura S, Inagami T, Senbonmatsu T (2011) Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res 34(6):701–706. doi:10.1038/hr.2011.19 PubMed

34.

Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M, Loibner H, Wang XH, Penninger JM, Kassiri Z, Oudit GY (2010) Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 122(7):717–728. doi:10.1161/CIRCULATIONAHA.110.955369 718 p following 728PubMed

35.

Beyer AM, Guo DF, Rahmouni K (2013) Prolonged treatment with angiotensin 1–7 improves endothelial function in diet-induced obesity. J Hypertens 31(4):730–738. doi:10.1097/HJH.0b013e32835ecbe5 PubMed

36.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87(5):E1–E9PubMed

37.

McKinney CA, Fattah C, Loughrey CM, Milligan G, Nicklin SA (2014) Angiotensin-(1–7) and angiotensin-(1–9): function in cardiac and vascular remodelling. Clin Sci 126(12):815–827. doi:10.1042/CS20130436 PubMed

38.

Ocaranza MP, Moya J, Barrientos V, Alzamora R, Hevia D, Morales C, Pinto M, Escudero N, Garcia L, Novoa U, Ayala P, Diaz-Araya G, Godoy I, Chiong M, Lavandero S, Jalil JE, Michea L (2014) Angiotensin-(1–9) reverses experimental hypertension and cardiovascular damage by inhibition of the angiotensin converting enzyme/Ang II axis. J Hypertens 32(4):771–783. doi:10.1097/HJH.0000000000000094 PubMed

39.

Flores-Munoz M, Work LM, Douglas K, Denby L, Dominiczak AF, Graham D, Nicklin SA (2012) Angiotensin-(1–9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 59(2):300–307. doi:10.1161/HYPERTENSIONAHA.111.177485 PubMed

40.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277(17):14838–14843. doi:10.1074/jbc.M200581200 PubMed

41.

Rastaldo R, Cappello S, Folino A, Berta GN, Sprio AE, Losano G, Samaja M, Pagliaro P (2011) Apelin-13 limits infarct size and improves cardiac postischemic mechanical recovery only if given after ischemia. Am J Physiol Heart Circ Physiol 300(6):H2308–H2315. doi:10.1152/ajpheart.01177.2010 PubMed

42.

Inui M, Fukui A, Ito Y, Asashima M (2006) Xapelin and Xmsr are required for cardiovascular development in Xenopus laevis. Dev Biol 298(1):188–200. doi:10.1016/j.ydbio.2006.06.028 PubMed

43.

Wang IN, Wang X, Ge X, Anderson J, Ho M, Ashley E, Liu J, Butte MJ, Yazawa M, Dolmetsch RE, Quertermous T, Yang PC (2012) Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. PLoS One 7(6):e38328. doi:10.1371/journal.pone.0038328 PubMedCentralPubMed

44.

Kang Y, Kim J, Anderson JP, Wu J, Gleim SR, Kundu RK, McLean DL, Kim JD, Park H, Jin SW, Hwa J, Quertermous T, Chun HJ (2013) Apelin-APJ signaling is a critical regulator of endothelial MEF2 activation in cardiovascular development. Circ Res 113(1):22–31. doi:10.1161/CIRCRESAHA.113.301324 PubMedCentralPubMed

45.

Saint-Geniez M, Masri B, Malecaze F, Knibiehler B, Audigier Y (2002) Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels. Mech Dev 110(1–2):183–186PubMed

46.

Devic E, Rizzoti K, Bodin S, Knibiehler B, Audigier Y (1999) Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human APJ. Mech Dev 84(1–2):199–203PubMed

47.

Devic E, Paquereau L, Vernier P, Knibiehler B, Audigier Y (1996) Expression of a new G protein-coupled receptor X-msr is associated with an endothelial lineage in Xenopus laevis. Mech Dev 59(2):129–140PubMed

48.

Cox CM, Dâ€™Agostino SL, Miller MK, Heimark RL, Krieg PA (2006) Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo. Dev Biol 296(1):177–189. doi:10.1016/j.ydbio.2006.04.452 PubMed

49.

Saint-Geniez M, Argence CB, Knibiehler B, Audigier Y (2003) The msr/apj gene encoding the apelin receptor is an early and specific marker of the venous phenotype in the retinal vasculature. Gene Expr Patterns GEP 3(4):467–472

50.

Kojima Y, Quertermous T (2008) Apelin-APJ signaling in retinal angiogenesis. Arterioscler Thromb Vasc Biol 28(10):1687–1688. doi:10.1161/ATVBAHA.108.174847 PubMedCentralPubMed

51.

Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T, Hinuma S, Baba A (2004) Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 325(2):395–400. doi:10.1016/j.bbrc.2004.10.042 PubMed

52.

Yang X, Zhu W, Zhang P, Chen K, Zhao L, Li J, Wei M, Liu M (2014) Apelin-13 stimulates angiogenesis by promoting crosstalk between AMP-activated protein kinase and Akt signaling in myocardial microvascular endothelial cells. Molecular Med Rep 9(5):1590–1596. doi:10.3892/mmr.2014.1984

53.

Kidoya H, Naito H, Takakura N (2010) Apelin induces enlarged and nonleaky blood vessels for functional recovery from ischemia. Blood 115(15):3166–3174. doi:10.1182/blood-2009-07-232306 PubMed

54.

Wang W, McKinnie SM, Patel VB, Haddad G, Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, Penninger JM, Kassiri Z, Vederas JC, Murray AG, Oudit GY (2013) Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia–reperfusion injury: therapeutic potential of synthetic Apelin analogues. J Am Heart Assoc 2(4):e000249. doi:10.1161/JAHA.113.000249 PubMedCentralPubMed

55.

Lin Q, Schwarz J, Bucana C, Olson EN (1997) Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C. Science 276(5317):1404–1407PubMedCentralPubMed

56.

Naya FJ, Black BL, Wu H, Bassel-Duby R, Richardson JA, Hill JA, Olson EN (2002) Mitochondrial deficiency and cardiac sudden death in mice lacking the MEF2A transcription factor. Nat Med 8(11):1303–1309. doi:10.1038/nm789 PubMed

57.

Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM (2002) Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation 105(18):2185–2191PubMed

58.

Cooke JP, Losordo DW (2002) Nitric oxide and angiogenesis. Circulation 105(18):2133–2135PubMed

59.

Kidoya H, Ueno M, Yamada Y, Mochizuki N, Nakata M, Yano T, Fujii R, Takakura N (2008) Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. EMBO J 27(3):522–534. doi:10.1038/sj.emboj.7601982 PubMedCentralPubMed

60.

Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N, Fukamizu A (2004) Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279(25):26274–26279. doi:10.1074/jbc.M404149200 PubMed

61.

Feng JH, Li WM, Wu XP, Tan XY, Gao YH, Han CL, Li SQ, Xie HN (2010) Hemodynamic effect of apelin in a canine model of acute pulmonary thromboembolism. Peptides 31(9):1772–1778. doi:10.1016/j.peptides.2010.06.004 PubMed

62.

Kagiyama S, Fukuhara M, Matsumura K, Lin Y, Fujii K, Iida M (2005) Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept 125(1–3):55–59. doi:10.1016/j.regpep.2004.07.033 PubMed

63.

Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP (2001) [(125)I]-(Pyr(1))Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol 132(6):1255–1260. doi:10.1038/sj.bjp.0703939 PubMedCentralPubMed

64.

Nagano K, Ishida J, Unno M, Matsukura T, Fukamizu A (2013) Apelin elevates blood pressure in ICR mice with LNAME induced endothelial dysfunction. Mol Med Rep 7(5):1371–1375. doi:10.3892/mmr.2013.1378 PubMedCentralPubMed

65.

Han X, Zhang DL, Yin DX, Zhang QD, Liu WH (2013) Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can J Physiol Pharmacol 91(9):708–714. doi:10.1139/cjpp-2013-0046 PubMed

66.

Gurzu B, Petrescu BC, Costuleanu M, Petrescu G (2006) Interactions between apelin and angiotensin II on rat portal vein. J Renin Angiotensin Aldosterone Syst JRAAS 7(4):212–216. doi:10.3317/jraas.2006.040

67.

Pitkin SL, Maguire JJ, Kuc RE, Davenport AP (2010) Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol 160(7):1785–1795. doi:10.1111/j.1476-5381.2010.00821.x PubMedCentralPubMed

68.

Zhong JC, Yu XY, Huang Y, Yung LM, Lau CW, Lin SG (2007) Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovasc Res 74(3):388–395. doi:10.1016/j.cardiores.2007.02.002 PubMed

69.

Rastaldo R, Cappello S, Folino A, Losano G (2011) Effect of apelin–apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool? Antioxid Redox Signal 14(5):909–922. doi:10.1089/ars.2010.3355 PubMed

70.

Japp AG, Newby DE (2008) The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75(10):1882–1892. doi:10.1016/j.bcp.2007.12.015 PubMed

71.

Ladeiras-Lopes R, Ferreira-Martins J, Leite-Moreira AF (2008) The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications. Arq Bras Cardiol 90(5):343–349PubMed

72.

Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, Toya Y, Fukamizu A, Kitamura H, Umemura S (2006) Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 26(6):1267–1272. doi:10.1161/01.ATV.0000218841.39828.91 PubMed

73.

Modgil A, Guo L, Oâ€™Rourke ST, Sun C (2013) Apelin-13 inhibits large-conductance Ca²⁺-activated K⁺ channels in cerebral artery smooth muscle cells via a PI3-kinase dependent mechanism. PLoS One 8(12):e83051. doi:10.1371/journal.pone.0083051 PubMedCentralPubMed

74.

Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H, Pikkarainen S, Piuhola J, Rysa J, Toth M, Ruskoaho H (2002) Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91(5):434–440PubMed

75.

Perjes A, Skoumal R, Tenhunen O, Konyi A, Simon M, Horvath IG, Kerkela R, Ruskoaho H, Szokodi I (2014) Apelin increases cardiac contractility via protein kinase C epsilon- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One 9(4):e93473. doi:10.1371/journal.pone.0093473 PubMedCentralPubMed

76.

Ronkainen VP, Ronkainen JJ, Hanninen SL, Leskinen H, Ruas JL, Pereira T, Poellinger L, Vuolteenaho O, Tavi P (2007) Hypoxia inducible factor regulates the cardiac expression and secretion of apelin. FASEB J 21(8):1821–1830. doi:10.1096/fj.06-7294com PubMed

77.

Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8(4):355–360. doi:10.1016/j.ejheart.2005.10.007 PubMed

78.

Wang M, Gupta RC, Rastogi S, Kohli S, Sabbah MS, Zhang K, Mohyi P, Hogie M, Fischer Y, Sabbah HN (2013) Effects of acute intravenous infusion of apelin on left ventricular function in dogs with advanced heart failure. J Cardiac Fail 19(7):509–516. doi:10.1016/j.cardfail.2013.05.004

79.

Dai T, Ramirez-Correa G, Gao WD (2006) Apelin increases contractility in failing cardiac muscle. Eur J Pharmacol 553(1–3):222–228. doi:10.1016/j.ejphar.2006.09.034 PubMedCentralPubMed

80.

Mathar I, Kecskes M, Van der Mieren G, Jacobs G, Camacho Londono JE, Uhl S, Flockerzi V, Voets T, Freichel M, Nilius B, Herijgers P, Vennekens R (2014) Increased beta-adrenergic inotropy in ventricular myocardium from Trpm4âˆ’/âˆ’ mice. Circ Res 114(2):283–294. doi:10.1161/CIRCRESAHA.114.302835 PubMed

81.

Bers DM (2002) Cardiac excitation-contraction coupling. Nature 415(6868):198–205. doi:10.1038/415198a PubMed

82.

Katz AM, Lorell BH (2000) Regulation of cardiac contraction and relaxation. Circulation 102(20 Suppl 4):IV69–IV74PubMed

83.

Dorn GW 2nd (2010) Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 90(3):1013–1062. doi:10.1152/physrev.00001.2010 PubMed

84.

Wang C, Du JF, Wu F, Wang HC (2008) Apelin decreases the SR Ca²⁺ content but enhances the amplitude of [Ca²⁺]i transient and contractions during twitches in isolated rat cardiac myocytes. Am J Physiol Heart Circ Physiol 294(6):H2540–H2546. doi:10.1152/ajpheart.00046.2008 PubMed

85.

Karmazyn M, Gan XT, Humphreys RA, Yoshida H, Kusumoto K (1999) The myocardial Na(+)-H(+) exchange: structure, regulation, and its role in heart disease. Circ Res 85(9):777–786PubMed

86.

Kojda G, Kottenberg K, Nix P, Schluter KD, Piper HM, Noack E (1996) Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 78(1):91–101PubMed

87.

Rastaldo R, Pagliaro P, Cappello S, Penna C, Mancardi D, Westerhof N, Losano G (2007) Nitric oxide and cardiac function. Life Sci 81(10):779–793. doi:10.1016/j.lfs.2007.07.019 PubMed

88.

Jia YX, Pan CS, Zhang J, Geng B, Zhao J, Gerns H, Yang J, Chang JK, Tang CS, Qi YF (2006) Apelin protects myocardial injury induced by isoproterenol in rats. Regul Pept 133(1–3):147–154. doi:10.1016/j.regpep.2005.09.033 PubMed

89.

Tendera M (2004) The epidemiology of heart failure. J Renin Angiotensin Aldosterone Syst JRAAS 5(Suppl 1):S2–S6. doi:10.3317/jraas.2004.020

90.

Piper HM, Abdallah Y, Schafer C (2004) The first minutes of reperfusion: a window of opportunity for cardioprotection. Cardiovasc Res 61(3):365–371. doi:10.1016/j.cardiores.2003.12.012 PubMed

91.

Zweier J, Rayburn B, Flaherty J, Weisfeldt M (1987) Recombinant superoxide dismutase reduces oxygen free radical concentrations in reperfused myocardium. J Clin Invest 80:1728–1734PubMedCentralPubMed

92.

Tao J, Zhu W, Li Y, Xin P, Li J, Liu M, Li J, Redington AN, Wei M (2011) Apelin-13 protects the heart against ischemia–reperfusion injury through inhibition of ER-dependent apoptotic pathways in a time-dependent fashion. Am J Physiol Heart Circ Physiol 301(4):H1471–H1486. doi:10.1152/ajpheart.00097.2011 PubMed

93.

Kleinz MJ, Baxter GF (2008) Apelin reduces myocardial reperfusion injury independently of PI3K/Akt and P70S6 kinase. Regul Pept 146(1–3):271–277. doi:10.1016/j.regpep.2007.10.002 PubMed

94.

Pisarenko OI, Lankin VZ, Konovalova GG, Serebryakova LI, Shulzhenko VS, Timoshin AA, Tskitishvili OV, Pelogeykina YA, Studneva IM (2014) Apelin-12 and its structural analog enhance antioxidant defense in experimental myocardial ischemia and reperfusion. Mol Cell Biochem 391(1–2):241–250. doi:10.1007/s11010-014-2008-4 PubMed

95.

Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ, Tang CS (2009) Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 30(6):1144–1152. doi:10.1016/j.peptides.2009.02.010 PubMed

96.

Smith CC, Mocanu MM, Bowen J, Wynne AM, Simpkin JC, Dixon RA, Cooper MB, Yellon DM (2007) Temporal changes in myocardial salvage kinases during reperfusion following ischemia: studies involving the cardioprotective adipocytokine apelin. Cardiovasc Drugs Ther 21(6):409–414. doi:10.1007/s10557-007-6054-y PubMed

97.

Hausenloy DJ, Yellon DM (2007) Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther 116(2):173–191. doi:10.1016/j.pharmthera.2007.06.005 PubMed

98.

Hamada H, Suzuki M, Yuasa S, Mimura N, Shinozuka N, Takada Y, Suzuki M, Nishino T, Nakaya H, Koseki H, Aoe T (2004) Dilated cardiomyopathy caused by aberrant endoplasmic reticulum quality control in mutant KDEL receptor transgenic mice. Mol Cell Biol 24(18):8007–8017. doi:10.1128/MCB.24.18.8007-8017.2004 PubMedCentralPubMed

99.

Tang SY, Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Zhou HD, Wu XP, Liao EY (2007) Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways. Peptides 28(3):708–718. doi:10.1016/j.peptides.2006.10.005 PubMed

100.

Andersen CU, Hilberg O, Mellemkjaer S, Nielsen-Kudsk JE, Simonsen U (2011) Apelin and pulmonary hypertension. Pulm Circ 1(3):334–346. doi:10.4103/2045-8932.87299 PubMedCentralPubMed

101.

Alastalo TP, Li M, de Jesus Perez V, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M (2011) Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 121(9):3735–3746. doi:10.1172/JCI43382 PubMedCentralPubMed

102.

Cui RR, Mao DA, Yi L, Wang C, Zhang XX, Xie H, Wu XP, Liao XB, Zhou H, Meng JC, Yuan LQ, Liao EY (2010) Apelin suppresses apoptosis of human vascular smooth muscle cells via APJ/PI3-K/Akt signaling pathways. Amino Acids 39(5):1193–1200. doi:10.1007/s00726-010-0555-x PubMed

103.

Zeng X, Yu SP, Taylor T, Ogle M, Wei L (2012) Protective effect of apelin on cultured rat bone marrow mesenchymal stem cells against apoptosis. Stem cell Res 8(3):357–367. doi:10.1016/j.scr.2011.12.004 PubMedCentralPubMed

104.

Khaksari M, Aboutaleb N, Nasirinezhad F, Vakili A, Madjd Z (2012) Apelin-13 protects the brain against ischemic reperfusion injury and cerebral edema in a transient model of focal cerebral ischemia. J Mol Neurosci 48(1):201–208. doi:10.1007/s12031-012-9808-3 PubMed

105.

Yang Y, Zhang X, Cui H, Zhang C, Zhu C, Li L (2014) Apelin-13 protects the brain against ischemia/reperfusion injury through activating PI3K/Akt and ERK1/2 signaling pathways. Neurosci Lett 568:44–49. doi:10.1016/j.neulet.2014.03.037 PubMed

106.

Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, Qian X, Yu J, Li Y, Xu X, Liu CF (2013) Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 63(6):535–540. doi:10.1016/j.neuint.2013.09.017 PubMed

107.

Antushevich H, Pawlina B, Kapica M, Krawczynska A, Herman AP, Kuwahara A, Kato I, Zabielski R (2013) Influence of fundectomy and intraperitoneal or intragastric administration of apelin on apoptosis, mitosis, and DNA repair enzyme OGG1,2 expression in adult rats gastrointestinal tract and pancreas. J Physiol Pharmacol 64(4):423–428PubMed

108.

Xie H, Yuan LQ, Luo XH, Huang J, Cui RR, Guo LJ, Zhou HD, Wu XP, Liao EY (2007) Apelin suppresses apoptosis of human osteoblasts. Apoptosis 12(1):247–254. doi:10.1007/s10495-006-0489-7 PubMed

109.

Zhang Z, Yu B, Tao GZ (2009) Apelin protects against cardiomyocyte apoptosis induced by glucose deprivation. Chin Med J 122(19):2360–2365PubMed

110.

Pchejetski D, Foussal C, Alfarano C, Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH, Wanecq E, Valet P, Parini A, Kunduzova O (2012) Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1. Eur Heart J 33(18):2360–2369. doi:10.1093/eurheartj/ehr389 PubMed

111.

Koguchi W, Kobayashi N, Takeshima H, Ishikawa M, Sugiyama F, Ishimitsu T (2012) Cardioprotective effect of apelin-13 on cardiac performance and remodeling in end-stage heart failure. Circ J 76(1):137–144PubMed

112.

Siwik DA, Chang DL, Colucci WS (2000) Interleukin-1beta and tumor necrosis factor-alpha decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 86(12):1259–1265PubMed

113.

Kim S, Iwao H (2000) Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52(1):11–34PubMed

114.

Sopel MJ, Rosin NL, Lee TD, Legare JF (2011) Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells. Lab Invest 91(4):565–578. doi:10.1038/labinvest.2010.190 PubMed

115.

Gordon JW, Shaw JA, Kirshenbaum LA (2011) Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res 108(9):1122–1132. doi:10.1161/CIRCRESAHA.110.226928 PubMed

116.

Barnes GD, Alam S, Carter G, Pedersen CM, Lee KM, Hubbard TJ, Veitch S, Jeong H, White A, Cruden NL, Huson L, Japp AG, Newby DE (2013) Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail 6(3):482–491. doi:10.1161/CIRCHEARTFAILURE.111.000077 PubMed

117.

Sorli SC, Le Gonidec S, Knibiehler B, Audigier Y (2007) Apelin is a potent activator of tumour neoangiogenesis. Oncogene 26(55):7692–7699. doi:10.1038/sj.onc.1210573 PubMed

118.

Yang L, Su T, Lv D, Xie F, Liu W, Cao J, Sheikh IA, Qin X, Li L, Chen L (2014) ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim Biophys Sin 46(2):100–111. doi:10.1093/abbs/gmt140 PubMed

Titel: Effects of apelin on the cardiovascular system
verfasst von: Anna Folino
Pier Giorgio Montarolo
Michele Samaja
Raffaella Rastaldo
Publikationsdatum: 01.07.2015
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 4/2015
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-015-9475-x

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Effects of apelin on the cardiovascular system

Abstract

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

T-wave/QRS complex amplitude correlations with myocardial edema in patients with takotsubo syndrome

Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations

BAG3: a new player in the heart failure paradigm

Acid–base and electrolyte abnormalities in heart failure: pathophysiology and implications

High salt intake as a multifaceted cardiovascular disease: new support from cellular and molecular evidence

Right ventricular failure due to chronic pressure load: What have we learned in animal models since the NIH working group statement?

Neu im Fachgebiet Kardiologie

Die „Zehn Gebote“ des Endokarditis-Managements

Strenge Blutdruckeinstellung lohnt auch im Alter noch

Sind Frauen die fähigeren Ärzte?

Dihydropyridin-Kalziumantagonisten können auf die Nieren gehen

Update Kardiologie